Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02503735 · ClinicalTrials.gov registry record · NA
Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT02503735: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT02503735 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02503735, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Treatment protocol to see if people with hepatitis C (HCV) and chronic kidney disease (CKD) who are treated with Harvoni for 12 weeks have improvements in their kidney disease.
Interventions
- DRUG Sofosbuvir/Ledipasvir FDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-07-15 |
| Est. Completion | 2019-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02503735
The ClinicalTrials.gov registry entry for NCT02503735 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sofosbuvir/Ledipasvir FDC is the first listed.
NCT02503735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02503735 about?
NCT02503735 is a clinical study titled "Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)". Treatment protocol to see if people with hepatitis C (HCV) and chronic kidney disease (CKD) who are treated with Harvoni for 12 weeks have improvements in their kidney disease.
What is the current status of trial NCT02503735?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2015-07-15. Estimated completion is 2019-05.
What interventions are being tested in trial NCT02503735?
The interventions under investigation include: Sofosbuvir/Ledipasvir FDC (DRUG).
Who is sponsoring clinical trial NCT02503735?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.